Fate Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference
February 12 2018 - 4:01PM
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage
biopharmaceutical company dedicated to the development of
first-in-class cellular immunotherapies for cancer and immune
disorders, announced today that Scott Wolchko, President and Chief
Executive Officer, will participate in a fireside chat at the
Leerink Partners 7th Annual Global Healthcare Conference in New
York on Thursday, February 15, 2018 at 9:30 a.m. ET.
A live webcast of the presentation will be
available through the investor relations section of the Company's
website at www.fatetherapeutics.com. Following the live webcast, an
archived replay will be available on the Company's website.
About Fate Therapeutics, Inc. Fate
Therapeutics is a clinical-stage biopharmaceutical company
dedicated to the development of first-in-class cellular
immunotherapies for cancer and immune disorders. The Company is
pioneering the development of off-the-shelf cell therapies using
its proprietary induced pluripotent stem cell (iPSC) product
platform. This platform uniquely enables the single-cell selection
of a precisely engineered iPSC clone and the subsequent creation
and maintenance of a clonal master iPSC line. Analogous to master
cell lines used to manufacture biopharmaceutical drug products such
as monoclonal antibodies, clonal master iPSC lines are a renewable
source for generating homogeneous cell products in quantities that
support the treatment of many thousands of patients in an
off-the-shelf manner. The Company’s immuno-oncology pipeline is
comprised of FATE-NK100, a donor-derived natural killer (NK) cell
cancer immunotherapy that is currently being evaluated in three
Phase 1 clinical trials, as well as other NK cell and T-cell
immunotherapies, with a focus on developing augmented cell products
intended to synergize with checkpoint inhibitor and monoclonal
antibody therapies. The Company’s immuno-regulatory pipeline
includes ProTmune™, a next-generation donor cell graft that is
currently being evaluated in a Phase 2 clinical trial for the
prevention of graft-versus-host disease, and a myeloid-derived
suppressor cell immunotherapy to promote immune tolerance in
patients with immune disorders. Fate Therapeutics is headquartered
in San Diego, CA. For more information, please visit
www.fatetherapeutics.com.
Contact: Christina Tartaglia Stern
Investor Relations, Inc. 212.362.1200 christina@sternir.com
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Apr 2023 to Apr 2024